Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spencer Pharmaceutical, a US based pharmaceutical R&D firm, has entered into an agreement with Polyvalor to further develop the technologies protected by two patent applications developed by Michael Buschmann and co-workers at Ecole Polytechnique de Montreal.
Subscribe to our email newsletter
Spencer Pharmaceutical said the patents are related to platform technologies for the efficient delivery of nucleic acids using chitosan as well as for an innovative discovery of therapeutic nanocomplexes for type 2 diabetes treatment in addition to other possible derivative applications.
Spencer Pharmaceutical CEO Arella said they are proud of having concluded this negotiation with Polyvalor and the Spencer team are looking forward to amalgamating the drug-discovery/delivery research of Buschmann’s group with the ongoing pipeline of drug-delivery systems development by Spencer that are already undergoing animal studies in their company.